Q32 Bio grabs $60M to kick off hu­man stud­ies for next-gen com­ple­ment drugs — with some Covid-19 tweaks along the way

For a com­pa­ny that launched in the ear­ly months of the pan­dem­ic, Q32 Bio had its fair share of run-ins with the new nor­mals un­der Covid-19.

The orig­i­nal plan, for in­stance, was to con­duct first-in-hu­man stud­ies of the IL-7 re­cep­tor an­ti­body it li­censed from Bris­tol My­ers Squibb in the Nether­lands. But they re­al­ized short­ly af­ter that while the coun­try was be­gin­ning to open up clin­i­cal tri­als, there were ad­di­tion­al re­stric­tions on drugs that tam­pered with im­muno­log­i­cal mech­a­nisms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.